Vida Ventures, LLC - Feb 12, 2024 Form 4 Insider Report for Kyverna Therapeutics, Inc. (KYTX)

Role
10%+ Owner
Signature
Vida Ventures, LLC By: /s/ Fred E. Cohen, its Senior Managing Director
Stock symbol
KYTX
Transactions as of
Feb 12, 2024
Transactions value $
$5,568,992
Form type
4
Date filed
2/14/2024, 07:04 PM
Previous filing
Feb 7, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KYTX Common Stock Conversion of derivative security +4.52M 4.52M Feb 12, 2024 By Vida Ventures, LLC F1, F2
transaction KYTX Common Stock Purchase $5.56M +253K $22.00* 253K Feb 12, 2024 By Vida Ventures III, L.P. F3
transaction KYTX Common Stock Purchase $12.8K +583 $22.00* 583 Feb 12, 2024 By Vida Ventures III-A, L.P. F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KYTX Series A-1 Redeemable Convertible Preferred Stock Conversion of derivative security $0 -4.4M -100% $0.00* 0 Feb 12, 2024 Common Stock 967K By Vida Ventures, LLC F2, F5
transaction KYTX Series A-2 Redeemable Convertible Preferred Stock Conversion of derivative security $0 -8.83M -100% $0.00* 0 Feb 12, 2024 Common Stock 1.94M By Vida Ventures, LLC F2, F5
transaction KYTX Series B Redeemable Convertible Preferred Stock Conversion of derivative security $0 -7.36M -100% $0.00* 0 Feb 12, 2024 Common Stock 1.62M By Vida Ventures, LLC F2, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's Common Stock received upon conversion of shares of the reported series of preferred stock on a 1-for-4.5511 basis without payment of further consideration.
F2 The shares of the Issuer's Common Stock are held directly by Vida Ventures, LLC. Vida Ventures Advisors, LLC is the investment advisor to Vida Ventures, LLC. Dr. Arie Belldegrun, Leonard Potter and Dr. Fred E. Cohen, a member of the Issuer's board of directors, are the managing members of Vida Ventures Advisors, LLC, and may be deemed to share voting and dispositive power over the shares held by Vida Ventures, LLC, but each disclaims beneficial ownership of the shares held by Vida Ventures, LLC, except to the extent of such person's pecuniary interest therein, if any.
F3 The shares of the Issuer's Common Stock are held directly by Vida Ventures III, L.P. ("Vida III"). Vida Ventures GP III, L.L.C. ("Vida III GP") is the general partner of Vida III. Vida III GP disclaims beneficial ownership of the securities held by Vida III, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F4 The shares of the Issuer's Common Stock are held directly by Vida Ventures III-A, L.P. ("Vida III-A"). Vida III GP is the general partner of Vida III-A. Vida III GP disclaims beneficial ownership of the securities held by Vida III-A, and this report shall not be deemed an admission that they are the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of their pecuniary interest therein, if any.
F5 The Series A-1, Series A-2 and Series B Redeemable Convertible Preferred Stock had no expiration date and automatically converted into the Issuer's Common Stock on a 1-for-4.5511 basis immediately prior to the closing of the Issuer's initial public offering.